This meta-analysis comprehensively evaluated the safety and effectiveness of PCSK9 inhibitors in patients who were already receiving statin treatment, with a specific focus on the use of plaque phenotyping data in patients with acute coronary syndrome (ACS). This evidence concerns the gene PCSK9 and acute coronary syndrome.